'

""

.



[1].
:
1 (CB1)
rimonabant ,
, ,


[2,3].

. ,
120 mg,
60 mg.
,
,
. ,
[4]. ,
( )
:
,
(BMI) 30 kg/m2
, BMI 27 kg/m2
[1].
,
placebo
( 5.6 10.3 kg 4.1-6.6 kg placebo).
,
,
[1].

[5].


.
, ,
,
.

2012
:
(Qsymia) (Belviq).


.
10%
[6]. ,
, [7].
, (),
,
.
,
5HT2c, .
,
( )
. :
3% [6].

,
,
.
;

(, ..)
.
, ,
612 2
,
[8].
, .

, ,
, , .
Alzheimer Parkinson,
.
,
10% [9].
. ,
rimonabant,

,
[10].
, ,

,
,
.
8% [11], (FDA)
2011 Contrave,
.





.


Glucagon-like-peptide 1 (GLP-1)
,
PYY
[12].
GLP-1 L
,

. ,
, .

2
.
.
,

[13]. GLP-1

, ,
[14].
L
(
GLP-1) [12].

[15].
[10].
PYY L

[12].

.


[16].

. ,

3 [12].
, ,
,

[12]. Ghrelin O-acyltransferase
(GOAT)

[17].

.

, .
,
,

.

.


1. Ioannides-Demos LL, Proietto J, McNeil JJ. Pharmacotherapy for obesity. Drugs
2005;65:1391-1418.
2. Wierzbicki AS. Rimonabant: endocannabinoid inhibition for the metabolic
syndrome. Int J Clin Pract 2006; 60:1697-1706.
3. James WP, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP, TorpPedersen C, Sharma AM, Shepherd GM, Rode RA, Renz CL; SCOUT Investigators.
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N
Engl J Med 2010;363:905-917.
4. Halford JC. Clinical pharmacotherapy for obesity: current drugs and those in
advanced development. Curr Drug Targets 2004; 5:637-646.
5. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J. Effect of orlistat on
weight and body composition in obese adolescents: a randomized controlled trial.
JAMA 2005;293:2873-2883.
6. Heal DJ, Gosden J, Smith SL. What is the prognosis for new centrally-acting antiobesity drugs? Neuropharmacology 2012;63:132-146.
7. Davidson MH, Tonstad S, Oparil S, Schwiers M, Day WW, Bowden CH. Changes
in Cardiovascular Risk Associated With Phentermine and Topiramate ExtendedRelease in Participants With Comorbidities and a Body Mass Index 27 kg/m(2.). Am
J Cardiol 2013;111:1131-1138.
8. Kopelman P, Groot Gde H, Rissanen A, Rossner S, Toubro S, Palmer R, Hallam R,
Bryson A, Hickling RI. Weight loss, HbA1c reduction, and tolerability of cetilistat in
a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with
orlistat (Xenical). Obesity (Silver Spring) 2010;18:108-115.
9. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of
tesofensine on bodyweight loss, body composition, and quality of life in obese
patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:19061913.
10. Rodgers RJ, Tschp MH, Wilding JP. Anti-obesity drugs: past, present and future.
Dis Model Mech 2012;5:621-626.
11. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson
J, Kim DD, Dunayevich E; COR-I Study Group. Effect of naltrexone plus bupropion
on weight loss in overweight and obese adults (COR-I): a multicentre, randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605.
12. Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and
obesity. Nat Rev Endocrinol 2010;6:444-453.
13. Astrup A, Carraro R, Finer N, Harper A, Kunesova M, Lean ME, Niskanen L,
Rasmussen MF, Rissanen A, Rssner S, Savolainen MJ, Van Gaal L; NN8022-1807
Investigators. Safety, tolerability and sustained weight loss over 2 years with the
once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) 2012;36:843-854.
14. Tan TM, Field BC, McCullough KA, Troke RC, Chambers ES, Salem V,
Gonzalez Maffe J, Baynes KC, De Silva A, Viardot A, Alsafi A, Frost GS, Ghatei
MA, Bloom SR. Coadministration of glucagon-like Peptide-1 during glucagon
infusion in humans results in increased energy expenditure and amelioration of
hyperglycemia. Diabetes 2013;62:1131-1138.
15. Wynne K, Park AJ, Small CJ, Meeran K, Ghatei MA, Frost GS, Bloom SR.
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake
in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond)
2006;30:1729-1736.

16. Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K,

Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB, Amatruda
JM. Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese
adults. J Clin Endocrinol Metab 2007;92:1754-1757.
17. Yang J, Brown MS, Liang G, Grishin NV, Goldstein JL. Identification of the
acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone.
Cell 2008;132:387-396.

Rodgers RJ et al, Dis Model Mech 2012;5:621-626

Astrup A et al, Int J Obes (Lond) 2012;36:843-854


: QSYMIA (. Qnexa)


(;)

2012: FDA
(9/2012)
Heal DJ et al, Neuropharmacology 2012;63:132-146